Aadi Bioscience’s lead investigational drug candidate product nab-sirolimus leverages albumin-bound nanoparticle technology that is based on similar technology as ABRAXANE® (nab-paclitaxel; Abraxis Bioscience acquired by Celgene Corp in 2010)
Albumin is accumulated in tumor tissues, either due to the leaky capillary system and defective lymphatic drainage of tumors  or through an active gp60/caveolae-mediated transport process across tumor blood vessel endothelium [2, 3]. Importantly, albumin is taken up by proliferating tumor cells via endocytosis and macropinocytosis, then catabolized by lysosomal degradation to support de novo protein synthesis, energy, and tumor growth . The accumulation of albumin in solid tumors provides potential rationale for albumin-based drug delivery systems to preferentially target tumors.
 Kratz F (2008). J Control Release 132, 171-183.
 Desai N et al (2006). Clin Cancer Res 12, 1317-1324.
 Minshall RD et al (2000). J Cell Biol 150, 1057-1070.
 Commisso C et al (2013). Nature 497, 633-637.
Preclinical Differentiation vs. Existing mTOR Inhibitors
In preclinical animal models, the nab technology investigational drug candidate nab-sirolimus has demonstrated advantages over existing mTOR inhibitors including: